{"DataElement":{"publicId":"10404369","version":"1","preferredName":"Hematopoietic Cell Transplantation Disease or Disorder Indication Acute Myeloid Leukemia Reason","preferredDefinition":"The specific indication for the hematopoietic cell transplantation for acute myeloid leukemia.","longName":"HCT_IND_AML_REA","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"10404358","version":"1","preferredName":"Hematopoietic Cell Transplantation Disease or Disorder Indication","preferredDefinition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","longName":"2659877v1.00:10404357v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2659877","version":"1","preferredName":"Stem Cell Transplantation","preferredDefinition":"A method of replacing the immature blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells.  The stem cells are given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells.","longName":"C15431","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"33BBDBD7-E7FD-4A2E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-25","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-06-25","modifiedBy":"ONEDATA","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"10404357","version":"1","preferredName":"Disease or Disorder Indication","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","longName":"C2991:C41184","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indication","conceptCode":"C41184","definition":"A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-3221-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-3222-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"10404362","version":"1","preferredName":"Acute Myeloid Leukemia Hematopoietic Cell Transplantation Indication Reason","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication)._An explanation of the cause of some phenomenon or action.","longName":"10404362v1.00","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"150","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"AML: CR1  FLT3/ITD+ with allelic ratio > 0.1 without bZIP CEBPA or  NPM1","valueDescription":null,"ValueMeaning":{"publicId":"10404363","version":"1","preferredName":"AML: CR1  FLT3/ITD+ with allelic ratio > 0.1 without bZIP CEBPA or  NPM1","longName":"10404363v1.00","preferredDefinition":"AML: CR1  FLT3/ITD+ with allelic ratio > 0.1 without bZIP CEBPA or  NPM1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-322A-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFDCA1E9-3230-2FB2-E053-731AD00A0138","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"AML: CR1 FLT3/ITD+ with allelic ratio > 0.1 with concurrent bZIP CEBPA or NPM1 and with MRD ≥ 0.05% at end of Induction 1","valueDescription":null,"ValueMeaning":{"publicId":"10404364","version":"1","preferredName":"AML: CR1 FLT3/ITD+ with allelic ratio > 0.1 with concurrent bZIP CEBPA or NPM1 and with MRD ≥ 0.05% at end of Induction 1","longName":"10404364v1.00","preferredDefinition":"AML: CR1 FLT3/ITD+ with allelic ratio > 0.1 with concurrent bZIP CEBPA or NPM1 and with MRD ≥ 0.05% at end of Induction 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-322B-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFDCA1E9-3231-2FB2-E053-731AD00A0138","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"AML: CR1 RAM phenotype or unfavorable prognostic markers regardless of favorable genetic markers, MRD, FLT3/ITD status","valueDescription":null,"ValueMeaning":{"publicId":"10404365","version":"1","preferredName":"AML: CR1 RAM phenotype or unfavorable prognostic markers regardless of favorable genetic markers, MRD, FLT3/ITD status","longName":"10404365v1.00","preferredDefinition":"AML: CR1 RAM phenotype or unfavorable prognostic markers regardless of favorable genetic markers, MRD, FLT3/ITD status","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-322C-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"CCURATOR","dateModified":"2022-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFDCA1E9-3232-2FB2-E053-731AD00A0138","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-23","deletedIndicator":"No"},{"value":"AML: CR1 without favorable or unfavorable cytogenetic or molecular features but with MRD ≥ 0.05% at end of Induction 1","valueDescription":null,"ValueMeaning":{"publicId":"10404366","version":"1","preferredName":"AML: CR1 without favorable or unfavorable cytogenetic or molecular features but with MRD ≥ 0.05% at end of Induction 1","longName":"10404366v1.00","preferredDefinition":"AML: CR1 without favorable or unfavorable cytogenetic or molecular features but with MRD ≥ 0.05% at end of Induction 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-322D-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFDCA1E9-3233-2FB2-E053-731AD00A0138","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"AML: CR1, non-ITD FLT3 activating mutation, MRD ≥ 0.05% at end of Induction 1 regardless of presence of favorable genetic markers","valueDescription":null,"ValueMeaning":{"publicId":"10404367","version":"1","preferredName":"AML: CR1, non-ITD FLT3 activating mutation, MRD ≥ 0.05% at end of Induction 1 regardless of presence of favorable genetic markers","longName":"10404367v1.00","preferredDefinition":"AML: CR1, non-ITD FLT3 activating mutation, MRD ≥ 0.05% at end of Induction 1 regardless of presence of favorable genetic markers","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-322E-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFDCA1E9-3234-2FB2-E053-731AD00A0138","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"AML in >/= CR2","valueDescription":null,"ValueMeaning":{"publicId":"10404368","version":"1","preferredName":"AML in >/= CR2","longName":"10404368v1.00","preferredDefinition":"AML in >/= CR2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-322F-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2023-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFDCA1E9-3235-2FB2-E053-731AD00A0138","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFDCA1E9-3236-2FB2-E053-731AD00A0138","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"10404361","version":"1","preferredName":"Acute Myeloid Leukemia Hematopoietic Cell Transplantation Indication Reason","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication)._An explanation of the cause of some phenomenon or action.","longName":"10404361v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Indication","conceptCode":"C41184","definition":"A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-3227-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-3228-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the indication for the hematopoietic cell transplantation for acute myeloid leukemia?","type":"Preferred Question Text","description":"What was the indication for the hematopoietic cell transplantation for acute myeloid leukemia?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Select the specific indication for HCT:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFDCA1E9-3239-2FB2-E053-731AD00A0138","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeDescription":null,"administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"}}